Corporate

Mar, 2023

News / Corporate

Mar 16, 2023

Phase 3 Study Shows XTANDI® (enzalutamide) plus Leuprolide Significantly Improves Metastasis-Free Survival in Men with Non-Metastatic Prostate Cancer

Pfizer and Astellas announce positive topline results from Phase 3 EMBARK trial NEW YORK and TOKYO, March 16, 2023 /PRNewswire/ -- Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503,...

News / Corporate

Mar 13, 2023

Astellas Announces Phase 3 China ARCHES Study of XTANDI® Meets Primary Endpoint

XTANDI® (enzalutamide) plus androgen deprivation therapy (ADT) significantly delays time to PSA progression compared to placebo plus ADT Study enrolled 180 men with metastatic hormone-sensitive...

News / Corporate

Mar 08, 2023

Astellas and BMT CTN Announce Topline Results from Phase 3 MORPHO Trial of Gilteritinib

Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) today announced topline results from...

Feb, 2023

News / Corporate

Feb 22, 2023

Astellas Announces Update on Preliminary Safety and Efficacy Data from FORTIS Study of Investigational AT845 in Adults with Late-Onset Pompe Disease

Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced an update on preliminary safety and efficacy data from its ongoing FORTIS Phase1/2 clinical...

News / Corporate

Feb 08, 2023

Astellas Commits to Achieve Net Zero Greenhouse Gas Emissions by 2050

Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced its commitment to achieve net zero greenhouse gas (GHG) emissions by 2050. Astellas is...